Loading clinical trials...
Loading clinical trials...
Randomized, Multicentric, Partially Double-Blinded Placebo-Controlled Phase II Study for Examining the Influence of Ribavirin on the Initial Virological Response With Treatment of Peginterferon Alfa-2a (40KD) and Ribavirin With a Six Week Pretreatment-Phase of Ribavirin/Placebo or PEG-Interferon Monotherapy in Treatment Naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection
Conditions
Interventions
Pegylated Interferon (PEG-IFN) alfa-2a
Placebo
+1 more
Locations
5
Germany
Berlin, Germany
Frankfurt am Main, Germany
Frankfurt am Main, Germany
Hanover, Germany
Homburg/ Saar, Germany
Start Date
April 1, 2007
Primary Completion Date
April 1, 2010
Completion Date
April 1, 2010
Last Updated
August 22, 2016
NCT05870969
NCT03987503
NCT04382404
NCT01226797
NCT00062816
NCT04774107
Lead Sponsor
Hoffmann-La Roche
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions